Sex-dependent treatment of chronic EAE with partial MHC class II constructs

Gil Benedek, Priya Chaudhary, Roberto Meza-Romero, Evan Calkins, Gail Kent, Halina Offner, Dennis Bourdette, Arthur Vandenbark

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: One of the main challenges in treating multiple sclerosis (MS) is reversing the effects of accumulated damage in the central nervous system (CNS) of progressive MS subjects. While most of the available drugs for MS subjects are anti-inflammatory and thus are limited to relapsing-remitting MS subjects, it is not clear to what extent their effects are capable of inducing axonal repair and remyelination in subjects with chronic MS. Methods: A chronic model of experimental autoimmune encephalomyelitis (EAE) was used to evaluate the potency of partial MHC (pMHC) class II constructs in treating progressive EAE. Results: We demonstrated an estrogen receptor alpha (ERα)-dependent increased dose requirement for effective treatment of female vs. male mice using pMHC. Such treatment using 100-μg doses of RTL342M or DRα1-mMOG-35-55 constructs significantly reversed clinical severity and showed a clear trend for inhibiting ongoing CNS damage, demyelination, and infiltration of inflammatory cells into the CNS in male mice. In contrast, WT female mice required larger 1-mg doses for effective treatment, although lower 100-μg doses were effective in ovariectomized or ERα-deficient mice with EAE. Conclusions: These findings will assist in the design of future clinical trials using pMHC for treatment of progressive MS.

Original languageEnglish (US)
Article number100
JournalJournal of Neuroinflammation
Volume14
Issue number1
DOIs
StatePublished - May 6 2017

Fingerprint

Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
Central Nervous System
Estrogen Receptor alpha
Relapsing-Remitting Multiple Sclerosis
Demyelinating Diseases
Anti-Inflammatory Agents
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Chronic experimental autoimmune encephalomyelitis (EAE)
  • DRα1-mMOG-35-55
  • Gender effect
  • Multiple sclerosis (MS)
  • RTL342M

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Sex-dependent treatment of chronic EAE with partial MHC class II constructs. / Benedek, Gil; Chaudhary, Priya; Meza-Romero, Roberto; Calkins, Evan; Kent, Gail; Offner, Halina; Bourdette, Dennis; Vandenbark, Arthur.

In: Journal of Neuroinflammation, Vol. 14, No. 1, 100, 06.05.2017.

Research output: Contribution to journalArticle

@article{3b798246243941589b038e35d574e4da,
title = "Sex-dependent treatment of chronic EAE with partial MHC class II constructs",
abstract = "Background: One of the main challenges in treating multiple sclerosis (MS) is reversing the effects of accumulated damage in the central nervous system (CNS) of progressive MS subjects. While most of the available drugs for MS subjects are anti-inflammatory and thus are limited to relapsing-remitting MS subjects, it is not clear to what extent their effects are capable of inducing axonal repair and remyelination in subjects with chronic MS. Methods: A chronic model of experimental autoimmune encephalomyelitis (EAE) was used to evaluate the potency of partial MHC (pMHC) class II constructs in treating progressive EAE. Results: We demonstrated an estrogen receptor alpha (ERα)-dependent increased dose requirement for effective treatment of female vs. male mice using pMHC. Such treatment using 100-μg doses of RTL342M or DRα1-mMOG-35-55 constructs significantly reversed clinical severity and showed a clear trend for inhibiting ongoing CNS damage, demyelination, and infiltration of inflammatory cells into the CNS in male mice. In contrast, WT female mice required larger 1-mg doses for effective treatment, although lower 100-μg doses were effective in ovariectomized or ERα-deficient mice with EAE. Conclusions: These findings will assist in the design of future clinical trials using pMHC for treatment of progressive MS.",
keywords = "Chronic experimental autoimmune encephalomyelitis (EAE), DRα1-mMOG-35-55, Gender effect, Multiple sclerosis (MS), RTL342M",
author = "Gil Benedek and Priya Chaudhary and Roberto Meza-Romero and Evan Calkins and Gail Kent and Halina Offner and Dennis Bourdette and Arthur Vandenbark",
year = "2017",
month = "5",
day = "6",
doi = "10.1186/s12974-017-0873-y",
language = "English (US)",
volume = "14",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Sex-dependent treatment of chronic EAE with partial MHC class II constructs

AU - Benedek, Gil

AU - Chaudhary, Priya

AU - Meza-Romero, Roberto

AU - Calkins, Evan

AU - Kent, Gail

AU - Offner, Halina

AU - Bourdette, Dennis

AU - Vandenbark, Arthur

PY - 2017/5/6

Y1 - 2017/5/6

N2 - Background: One of the main challenges in treating multiple sclerosis (MS) is reversing the effects of accumulated damage in the central nervous system (CNS) of progressive MS subjects. While most of the available drugs for MS subjects are anti-inflammatory and thus are limited to relapsing-remitting MS subjects, it is not clear to what extent their effects are capable of inducing axonal repair and remyelination in subjects with chronic MS. Methods: A chronic model of experimental autoimmune encephalomyelitis (EAE) was used to evaluate the potency of partial MHC (pMHC) class II constructs in treating progressive EAE. Results: We demonstrated an estrogen receptor alpha (ERα)-dependent increased dose requirement for effective treatment of female vs. male mice using pMHC. Such treatment using 100-μg doses of RTL342M or DRα1-mMOG-35-55 constructs significantly reversed clinical severity and showed a clear trend for inhibiting ongoing CNS damage, demyelination, and infiltration of inflammatory cells into the CNS in male mice. In contrast, WT female mice required larger 1-mg doses for effective treatment, although lower 100-μg doses were effective in ovariectomized or ERα-deficient mice with EAE. Conclusions: These findings will assist in the design of future clinical trials using pMHC for treatment of progressive MS.

AB - Background: One of the main challenges in treating multiple sclerosis (MS) is reversing the effects of accumulated damage in the central nervous system (CNS) of progressive MS subjects. While most of the available drugs for MS subjects are anti-inflammatory and thus are limited to relapsing-remitting MS subjects, it is not clear to what extent their effects are capable of inducing axonal repair and remyelination in subjects with chronic MS. Methods: A chronic model of experimental autoimmune encephalomyelitis (EAE) was used to evaluate the potency of partial MHC (pMHC) class II constructs in treating progressive EAE. Results: We demonstrated an estrogen receptor alpha (ERα)-dependent increased dose requirement for effective treatment of female vs. male mice using pMHC. Such treatment using 100-μg doses of RTL342M or DRα1-mMOG-35-55 constructs significantly reversed clinical severity and showed a clear trend for inhibiting ongoing CNS damage, demyelination, and infiltration of inflammatory cells into the CNS in male mice. In contrast, WT female mice required larger 1-mg doses for effective treatment, although lower 100-μg doses were effective in ovariectomized or ERα-deficient mice with EAE. Conclusions: These findings will assist in the design of future clinical trials using pMHC for treatment of progressive MS.

KW - Chronic experimental autoimmune encephalomyelitis (EAE)

KW - DRα1-mMOG-35-55

KW - Gender effect

KW - Multiple sclerosis (MS)

KW - RTL342M

UR - http://www.scopus.com/inward/record.url?scp=85018421722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018421722&partnerID=8YFLogxK

U2 - 10.1186/s12974-017-0873-y

DO - 10.1186/s12974-017-0873-y

M3 - Article

C2 - 28477623

AN - SCOPUS:85018421722

VL - 14

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 100

ER -